z-logo
Premium
Beta blockers in patients with end‐stage renal disease—Evidence‐based recommendations
Author(s) -
Weir Matthew A.,
Herzog Charles A.
Publication year - 2018
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/sdi.12691
Subject(s) - medicine , observational study , hemodialysis , intensive care medicine , kidney disease , disease , beta (programming language) , beta blocker , heart failure , end stage renal disease , cardiology , drug class , adrenergic beta antagonists , drug , pharmacology , computer science , programming language , propranolol
For patients who require hemodialysis, beta blockers offer a simultaneous opportunity and challenge in the treatment of cardiovascular disease. Beta blockers are well supported by data from nondialysis populations and directly mitigate the sympathetic overactivity that links chronic kidney disease with cardiovascular sequelae. However, the evidence supporting their use in patients receiving hemodialysis is sparse and the heterogeneity of the beta blocker class makes it difficult to prescribe these medications with confidence. Despite these limitations, both trial and observational data exist that can help guide the use of these medications. In this review, we outline the reasons to consider beta blockers for patients receiving hemodialysis, discuss the barriers to their use, and provide specific evidence‐based recommendations for beta blocker use in patients with heart failure, hypertension, ischemic heart disease and arrhythmia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here